NCT00614848已完成不适用
Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions
Medtronic Vascular1 个研究点 分布在 1 个国家目标入组 1,200 人开始时间: 2003年6月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,200
- 试验地点
- 1
- 主要终点
- Target Vessel Failure Rate at 9 months post procedure
研究概览
简要总结
To demonstrate the safety and efficacy of the Driver Coronary Stent coated with 10 mcg/mm ABT-578 compared to the uncoated Driver Stent for the treatment of single de novo lesions in native coronary arteries 2.25-3.5 mm in diameter.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is an acceptable candidate for PTCA, stenting, and emergent CABG.
- •Subject must have clinical evidence of ischemic heart disease or a positive functional study.
- •Subject has single vessel disease or has multivessel disease with only moderate stenosis (max 50-60% or total occlusion (100%) for which no interventions are planned at the time of study inclusion).
- •Target lesion / vessel must meet the following criteria:
- •Target lesion is a single de novo lesion that has not been previously treated with any interventional procedure. Only one lesion may be treated per subject
- •Target vessel must be a native coronary artery with a stenosis of >=50% and <100%
- •Target lesion must be >= 14 mm and ≤ 27 mm in length
- •Target vessel reference diameter must be >= 2.25 mm and ≤3.5 mm
- •Female subjects of childbearing potential must have a negative pregnancy test within 7 days before the procedure.
- •Subject or subject's legal representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site
- •Subject and treating physician agree that subject will comply with all required post-procedure follow-up
排除标准
- •A documented left ventricular ejection fraction <30%
- •A known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, cobalt, nickel, chromium, or a sensitivity to contrast media, which cannot be adequately pre-medicated
- •History of an allergic reaction or significant sensitivity or receiving drugs similar to/or synergistic to ABT-578 (rapamycin, tacrolimus, sirolimus, CCI-779 or other analogues).
- •A platelet count <100,000 cells/mm³ or >700,000 cells/mm³, or a WBC <3,000 cells/mm³
- •Evidence of an acute myocardial infarction within 72 hours of the intended treatment (defined as: Q wave or non-Q wave infarction having CK enzymes >2X the upper laboratory normal with the presence of a CK-MB elevated above the Institution's upper limit of normal).
- •Creatinine >2.0 mg/dl
- •A previous coronary interventional procedure of any kind within the 30 days prior to the procedure
- •Subject requires planned interventional treatment of either the target or any non-target vessel within 30 days post-procedure
- •Target lesion requires treatment with a device other than PTCA prior to stent placement
- •Previous stenting anywhere in the target vessel
- •Target vessel has evidence of thrombus or is excessively tortuous (2 bends >90 degrees to reach the target lesion)
- •Significant (>50%) stenosis proximal or distal to the target lesion that might require revascularization or impede run off
- •Target lesion located in native vessel distally to anastomosis with vein graft or LIMA
- •Target lesion has any of the following characteristics:
- •Lesion location is aorto-ostial, an unprotected left main lesion, or within 5mm of the origin of the LAD, LCX, or RCA
- •Involves a side branch >2.0 mm in diameter
- •Is at or distal to a 45º bend in the vessel
- •Is severely calcified
- •Unprotected left main coronary artery disease (an obstruction greater than 50% in the left main coronary artery)
- •History of a stroke or transient ischemic attack within the prior 6 months
- •Active peptic ulcer or upper GI bleeding within the prior 6 months
- •The subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
- •Concurrent medical condition with a life expectancy of less than 12 months
- •Any previous or planned treatment with anti-restenotic therapies including, but not limited to, drug-eluting stents and brachytherapy
- •Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints
结局指标
主要结局
Target Vessel Failure Rate at 9 months post procedure
时间窗: 9 months
次要结局
- Device Success Lesion Success Procedure Success Major Cardiac Adverse Events (MACE) at 30 days and 6, 9, and 12 months, and annually thereafter out to 5 years. Late loss at 8 months as measured by QCA(30 days and 6, 9, and 12 months, and annually thereafter out to 5 years.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Trial of Bare Metal Stent - Cobalt Chromium Versus Stent Coating With SirolimusCoronary Artery DiseaseNCT01093391Scitech Produtos Medicos Ltda63
终止
不适用
Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery Disease (BEST)Coronary Artery DiseaseNCT00997828Seung-Jung Park888
招募中
不适用
Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary LithotripsyCoronary Artery DiseaseNCT06369142Deutsches Herzzentrum Muenchen666
已完成
1 期
Safety Study to Assess the FEasibility of Use of the TRYTON Bifurcation Coronary Stent System (SAFE-TRY)Angioplasty, Transluminal, Percutaneous CoronaryCoronary Artery DiseaseNCT01174433University of Padova241
已完成
不适用
A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary In-stent RestenosisCoronary In-stent RestenosisNCT03373695DK Medical Technology (Suzhou) Co., Ltd.260